静脉戈利木单抗治疗活动性银屑病关节炎的安全性与疗效:GO-VIBRANT研究24周结果
GO-VIBRANT是一项III期随机双盲安慰剂对照试验,评估静脉戈利木单抗2 mg/kg在活动性银屑病关节炎患者中的安全性和疗效。第14周,戈利木单抗组ACR20应答率显著高于安慰剂组(75.1% vs 21.8%,P<0.001),且ACR50、ACR70、PASI75应答及HAQ DI改善均更优。第24周,戈利木单抗组影像学进展较安慰剂组更少,不良事件类型与其他抗TNF药物一致。
要点
- 静脉戈利木单抗2 mg/kg显著改善活动性PsA的关节炎和皮损表现。
- 第14周ACR20应答率75.1%,安慰剂组21.8%,差异有统计学意义。
- 第24周戈利木单抗组影像学进展低于安慰剂组,安全性与其他抗TNF药物一致。
核心结论
- 静脉戈利木单抗2 mg/kg可显著改善活动性银屑病关节炎患者的症状体征并减少影像学进展,安全性与其他抗TNF药物一致。
研究设计与样本
- III期随机双盲安慰剂对照试验,患者随机接受静脉安慰剂(n=239)或戈利木单抗2 mg/kg(n=241),于第0、4、12、20周给药。
主要发现
- 第14周ACR20应答率戈利木单抗组75.1%,安慰剂组21.8%(P<0.001)。
- 第14周ACR50应答率43.6% vs 6.3%,ACR70应答率24.5% vs 2.1%,PASI75应答率59.2% vs 13.6%(均P<0.001)。
- 第14周HAQ DI评分平均变化戈利木单抗组-0.60,安慰剂组-0.12(P<0.001)。
- 第24周PsA-modified SHS总分平均变化戈利木单抗组-0.4,安慰剂组2.0(P<0.001)。
- 截至第24周,安慰剂组40.6%和戈利木单抗组46.3%的患者发生至少1次不良事件,感染最常见。
关键数值与推荐
- 主要终点为第14周达到ACR20应答的患者比例。
- 次要终点包括第14周HAQ DI评分变化、ACR50/ACR70应答率、PASI75应答率及第24周PsA-modified SHS总分变化。
临床怎么用
- 对于活动性银屑病关节炎患者,静脉戈利木单抗2 mg/kg可作为改善症状和抑制影像学进展的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of intravenous (IV) golimumab treatment in psoriatic arthritis (PsA). METHODS: In this phase III, randomized, double-blind, placebo-controlled trial, patients were randomly assigned to receive IV placebo (n = 239) or golimumab at 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 14. Controlled secondary end points included change from baseline in Health Assessment Questionnaire disability index (HAQ DI) score at week 14, proportions of patients with ACR50 and ACR70 responses and ≥75% improvement on the Psoriasis Area and Severity Index (a PASI75 response) at week 14, and change from baseline at week 24 in the total modified Sharp/van der Heijde score (SHS) with modifications for patients with PsA. RESULTS: At week 14, an ACR20 response was achieved by 75.1% of patients in the golimumab group compared with 21.8% of patients in the placebo group (P < 0.001). Greater proportions of golimumab-treated patients had an ACR50 response (43.6% versus 6.3%), an ACR70 response (24.5% versus 2.1%), and a PASI75 response (59.2% versus 13.6%) at week 14 (P < 0.001 for all). Patients in the golimumab group had greater mean changes at week 14 in HAQ DI score (-0.60 versus -0.12; P < 0.001). At week 24, the mean change in total PsA-modified SHS was -0.4 in the golimumab group and 2.0 in the placebo group (P < 0.001). Through week 24, 40.6% of patients in the placebo group and 46.3% of patients in the golimumab group had ≥1 adverse event (AE); infections were the most common type. CONCLUSION: Patients receiving IV golimumab at 2 mg/kg had significantly greater improvements in the signs and symptoms of PsA and less radiographic progression through week 24. AEs were consistent with those seen with other anti-tumor necrosis factor agents.
引用
- Kavanaugh A, Husni ME, Harrison DD, et al. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study. Arthritis Rheumatol. 2017. PMID: 28805045. doi:10.1002/art.40226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。